The Tesamorelin (6 mg) + CJC-1295 (No DAC) (3 mg) + Ipamorelin (3 mg) formulation, a 12 mg total blend is designed for research use only to investigate potential synergistic effects on growth hormone–releasing hormone (GHRH) stimulation. This combination is studied for its collective influence on metabolic function, fat oxidation, cellular repair, and endocrine regulation through the coordinated activation of GHRH and GHRP pathways.
This peptide blend is intended exclusively for laboratory research purposes and is not for human or veterinary use.
The Tesamorelin (6 mg) + CJC-1295 (No DAC) (3 mg) + Ipamorelin (3 mg) formulation, a 12 mg total blend is designed for research use only to investigate potential synergistic effects on growth hormone–releasing hormone (GHRH) stimulation. This combination is studied for its collective influence on metabolic function, fat oxidation, cellular repair, and endocrine regulation through the coordinated activation of GHRH and GHRP pathways.
This peptide blend is intended exclusively for laboratory research purposes and is not for human or veterinary use.
Disclaimer: This peptide is for research and educational purposes only. NOT FOR HUMAN CONSUMPTION. It is not intended for diagnostic or therapeutic use without the guidance of a qualified healthcare professional.
You must be 18 years of age or older to enter this website.
By entering this site, you confirm that you are at least 18 years old and understand that the products offered are intended for laboratory research purposes only and not for human consumption.
If you are under the age of 18, please exit this site immediately.
